Biovail Takes Aim At FDA Over Generic Wellbutrin

Law360, New York (August 24, 2006, 12:00 AM EDT) -- Biovail Corp. has filed suit against the U.S. Food and Drug Administration, underscoring that the company does not intend to surrender its lucrative branded drug Wellbutrin XL to generic companies without a vicious fight.

Biovail launched the lawsuit in the U.S. District Court for the District of Columbia on Wednesday, seeking a temporary restraining order and preliminary injunction. The company demanded that the FDA require strict testing of generic versions of Wellbutrin XL before approving any copycats of the drug.

The drug maker has already sued...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.